Labcorp (LH) to Spin Off Clinical Development Business
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- Oil rises 1% on US-Iran deal doubts; IEA warns of supply glut
Labcorp to Spin Off Clinical Development Business
July 28, 2022 6:59 AM EDTClinical Development Business to be a Leading, Pure-Play Contract Research Organization with a Comprehensive Set of Clinical Trial Management, Market Access and Technology Capabilities
Labcorp Remains a Leader in the Laboratory Market with Highly Complementary, Laboratory-Focused Businesses including Routine and Esoteric Labs, Central Labs and Early Development Research Labs
Transaction Designed to Create Value Through Enhanced Strategic and Operational Focus
Labcorp to Discuss Spin-off and Second Quarter 2022 Financial Results at 9:00 a.m. ET Today
BURLINGTON, N.C.--(BUSINESS... More
